https://oqory.com/ 2025-01-22T07:40:39+00:00 https://oqory.com/cookie-policy/ 2025-01-11T14:27:43+00:00 https://oqory.com/privacy-policy/ 2025-01-11T14:36:13+00:00 https://oqory.com/forward-looking-statements/ 2025-01-11T14:23:47+00:00 https://oqory.com/terms-of-use/ 2025-01-11T14:19:15+00:00 https://oqory.com/our-adc-program/ 2025-04-24T08:58:55+00:00 https://oqory.com/pipeline/ 2025-04-24T09:06:34+00:00 https://oqory.com/news-events/ 2025-04-24T08:55:35+00:00 https://oqory.com/kol-advisors/ 2025-04-24T09:11:33+00:00 https://oqory.com/leadership/ 2025-04-24T09:12:29+00:00 https://oqory.com/who-we-are/ 2025-04-24T09:08:42+00:00 https://oqory.com/contact-us/ 2025-04-24T08:51:00+00:00 https://oqory.com/team-members/henry-ji-phd/ 2025-04-24T08:46:16+00:00 https://oqory.com/oqory-to-present-at-the-oppenheimer-35th-annual-healthcare-life-sciences-conference/ 2025-02-11T03:43:18+00:00 https://oqory.com/team-members/xiao-xu-m-d/ 2025-01-13T02:48:06+00:00 https://oqory.com/pipelines/rtx/ 2024-09-17T01:30:06+00:00 https://oqory.com/pipelines/ovydsotm/ 2024-09-20T14:25:18+00:00 https://oqory.com/pipelines/fujoveetm/ 2024-09-17T01:28:13+00:00 https://oqory.com/pipelines/anti-tnf/ 2024-09-16T14:49:38+00:00 https://oqory.com/pipelines/pd-l1/ 2024-09-20T14:30:12+00:00 https://oqory.com/pipelines/cd38-dar-t/ 2024-09-16T15:29:43+00:00 https://oqory.com/pipelines/cd38-adc/ 2024-09-16T15:29:34+00:00 https://oqory.com/pipelines/trop2-adc/ 2024-09-16T15:29:23+00:00 https://oqory.com/pipelines/bcma-adc/ 2024-09-16T15:29:11+00:00 https://oqory.com/pipelines/bevacizumab-adnab-tm/ 2024-09-16T15:29:04+00:00 https://oqory.com/pipelines/rituximab-adnab-tm/ 2024-09-16T15:28:55+00:00 https://oqory.com/pipelines/seprehvectm-oncolytic-virus-tm/ 2024-09-16T15:28:47+00:00 https://oqory.com/pipelines/sofusa-anti-pd-1/ 2024-09-16T15:28:33+00:00 https://oqory.com/pipelines/anti-pd-1/ 2024-09-16T14:49:52+00:00 https://oqory.com/pipelines/lymphatics-indcyanine-green-dye/ 2024-09-20T14:32:25+00:00 https://oqory.com/morgan-stanley-20th-annual-global-healthcare-conference/ 2024-09-10T10:47:10+00:00 https://oqory.com/kol-event-new-horizons-for-the-treatment-of-non-small-cell-lung-cancer-2/ 2024-09-10T10:49:28+00:00 https://oqory.com/kol-event-empowering-the-lymphatics-unleashing-the-potential-of-biologics-that-target-the-immune-system-click-here/ 2024-09-10T10:04:01+00:00 https://oqory.com/scilex-holding-company-announces-that-its-majority-stockholder-sorrento-therapeutics-inc-has-issued-a-supplement-to-its-previously-issued-faq-regarding-the-dividend-of-scilex-hol/ 2024-09-10T10:03:16+00:00 https://oqory.com/sorrento-issues-supplement-to-its-previously-issued-faq-regarding-the-dividend-of-scilex-holding-company-common-stock/ 2024-09-10T10:02:43+00:00 https://oqory.com/sorrento-distributes-dividend-confirmation-statements-to-146-brokerage-firms-and-provides-specific-instruction-to-continental-stock-transfer-trust-company-regarding-the-dividend-of-scilex-holding-co/ 2024-09-10T10:02:22+00:00 https://oqory.com/scilex-holding-company-a-majority-owned-subsidiary-of-sorrento-therapeutics-inc-announces-record-and-meeting-dates-for-its-first-annual-meeting-of-stockholders/ 2024-09-10T10:02:01+00:00 https://oqory.com/joint-statement-by-sorrento-therapeutics-inc-and-scilex-holding-company-on-todays-isolated-chapter-11-filing-by-sorrento-therapeutics-inc/ 2024-09-10T10:01:38+00:00 https://oqory.com/report-of-organizational-actions-affecting-basis-of-securities-2/ 2024-09-10T10:01:13+00:00 https://oqory.com/sorrento-therapeutics-inc-receives-court-approval-for-first-day-employee-wages-and-cash-management-motions/ 2024-09-10T10:00:52+00:00 https://oqory.com/sorrento-issues-update-to-its-previously-issued-faq-regarding-the-dividend-of-scilex-holding-company-common-stock-nasdaq-sclx-scilex/ 2024-09-10T09:59:11+00:00 https://oqory.com/sorrento-posts-form-8937-to-supplement-its-previously-issued-faq-regarding-the-dividend-of-scilex-holding-company-common-stock-nasdaq-sclx-scilex/ 2024-09-10T09:58:43+00:00 https://oqory.com/sorrento-therapeutics-inc-receives-court-approval-for-75-million-financing-in-chapter-11-case/ 2024-09-10T09:58:05+00:00 https://oqory.com/anti-omicron-neutralization-antibody/ 2024-09-09T12:45:14+00:00 https://oqory.com/sorrento-sti-9167-and-sti-9199-anti-omicron-neutralization-antibody/ 2024-09-09T12:45:47+00:00 https://oqory.com/january-2023-corporate-presentation/ 2024-09-09T12:46:22+00:00 https://oqory.com/sti-dividend-faq/ 2024-09-09T12:46:56+00:00 https://oqory.com/supplement-to-dividend-faq/ 2024-09-09T12:47:29+00:00 https://oqory.com/report-of-organizational-actions-affecting-basis-of-securities/ 2024-09-09T12:48:02+00:00 https://oqory.com/vivasor-therapeutics-inc-receives-court-approval-for-75-million-financing-in-chapter-11-case/ 2024-09-09T08:27:08+00:00 https://oqory.com/vivasor-posts-form-8937-to-supplement-its-previously-issued-faq-regarding-the-dividend-of-scilex-holding-company-common-stock-nasdaq-sclx-scilex/ 2024-09-09T08:27:17+00:00 https://oqory.com/kol-event-new-horizons-for-the-treatment-of-non-small-cell-lung-cancer/ 2024-09-09T08:27:23+00:00